Neoadjuvant T-DXd produced faster imaging responses vs ddAC in DESTINY-Breast11, but imaging poorly predicted pCR.
|Videos|April 3, 2012
Conference Coverage From the ATA Annual Meeting
Author(s)Onclive Team
Conferencd coverage from the 82nd Annual Meeting of the American Thyroid Association (ATA).
Advertisement
Live coverage from the 82nd Annual Meeting of the American Thyroid Association (ATA) from September 19-23, 2012, at the Hilton Quebec and Quebec City Convention Centre, Quebec City, PQ, Canada.
The meeting featured cutting-edge educational sessions, great networking opportunities, and unmatched collegiality.
Find out more at
Not signed up to receive OncLive emails? Make an account today to make sure you don't miss updates from our conference coverage.
Advertisement
Related to this article
Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.
INCB123667 with bevacizumab showed antitumor activity in heavily pretreated, cyclin E1–overexpressing platinum-resistant ovarian cancer.
Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
The claudin 6–targeted antibody-drug conjugate ixotatug vedotin showed antitumor activity in recurrent germ cell tumors, including after transplant.
An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.
The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
2
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
3
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
4
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC
5